Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial. Liu Y, Lin N, Yi S, Huang H, et al. Int J Cancer 2025;156:2158-2168.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu Y, Lin N, Yi S, Huang H, et al. Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial. Int J Cancer 2025;156:2158-2168.
PMID: 40018797